RXRXRECURSION PHARMACEUTICALS, INC.
Biological Products, (no Diagnostic Substances)
- Revenue
- $75M
- 27% YoY
- Operating margin
- -867.9%
- 6.6% YoY
- EBITDA
- −$564M
- 28% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$541M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired149% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear13% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $10M | $40M | $45M | $59M | $75M | 27% |
| Operating income | −$183M | −$246M | −$350M | −$479M | −$648M | 35% |
| Net income | −$186M | −$239M | −$328M | −$464M | −$645M | 39% |
| Operating cash flow | −$159M | −$84M | −$288M | −$359M | −$372M | 3.5% |
| Capex | $40M | $37M | $12M | $14M | $6M | 53% |
| Stock-based comp | $15M | $28M | $54M | $82M | $111M | 36% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $446K · 3
- Net
- −$446K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $10M | $3M | 13 | 123 |
| FY2024 | $8M | $2M | 22 | 92 |
| FY2023 | $9M | $11M | 32 | 93 |
| FY2022 | $6M | −$6M | 25 | 89 |
| FY2021 | $674K | $22M | 55 | 99 |